Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Leases (2019 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Current Leases for 8 consecutive years, with $4.2 million as the latest value for Q1 2026.

  • For Q1 2026, Current Leases rose 13.01% year-over-year to $4.2 million; the TTM value through Mar 2026 reached $4.2 million, up 13.01%, while the annual FY2025 figure was $4.2 million, 45.6% up from the prior year.
  • Current Leases hit $4.2 million in Q1 2026 for Cartesian Therapeutics, up from $4.2 million in the prior quarter.
  • Across five years, Current Leases topped out at $4.2 million in Q1 2026 and bottomed at $1.1 million in Q1 2022.
  • Average Current Leases over 5 years is $2.5 million, with a median of $2.2 million recorded in 2024.
  • Year-over-year, Current Leases soared 66.17% in 2025 and then rose 13.01% in 2026.
  • Cartesian Therapeutics' Current Leases stood at $1.6 million in 2022, then skyrocketed by 34.7% to $2.2 million in 2023, then soared by 31.63% to $2.9 million in 2024, then skyrocketed by 45.6% to $4.2 million in 2025, then grew by 0.84% to $4.2 million in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $4.2 million, $4.2 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.